# US 2010/0305062 A1 · Use of alginate oligomers in combating biofilms

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2010/0305062 A1
- Document ID: US20100305062A1
- Status: Published application
- Kind: A1
- Application number: 12/745,058
- Filed: 2008-10-24
- Published: 2010-12-02
- Earliest claimed: 2007-11-27
- Assignees: Algipharma Ipr AS
- Inventors: Edvar ONSOYEN; Rolf MYRVOLD
- Web page: https://patentgrep.com/patent/US20100305062A1

## CPC

- A61K 31/734: Alginic acid
- A01N 43/16: with oxygen as the ring hetero atom
- A01N 63/50: Isolated enzymes; Isolated proteins (peptides A01N37/46)
- A01N 65/03: Algae
- A61K 8/66: Enzymes
- A61K 8/733: {Alginic acid; Salts thereof}
- A61K 31/65: Tetracyclines
- A61K 31/7036: having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
- A61K 38/4886: {Metalloendopeptidases (3.4.24), e.g. collagenase}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 1/02: Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 11/06: Antiasthmatics
- A61P 13/08: of the prostate
- A61P 17/02: for treating wounds, ulcers, burns, scars, keloids, or the like
- A61P 27/16: Otologicals
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P 31/02: Local antiseptics
- A61P 31/04: Antibacterial agents
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61Q 11/00: Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses
- A61Q 17/005: {Antimicrobial preparations}
- A61Q 19/007: {Preparations for dry skin}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A01N: PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF (preservation of food or foodstuff A23); BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES (preparations for medical, dental or toiletry purposes which kill or prevent the growth or proliferation of unwanted organisms A61K); PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61Q: SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS

## Abstract

The invention provides a method for combating biofilm, said method comprising contacting a biofilm with an alginate oligomer. The biofilm may be on an animate or inanimate surface and both medical and non-medical uses and methods are provided. In one aspect the invention provides an alginate oligomer for use in the treatment or prevention of a biofilm infection in a subject. In another aspect the method can be used to combat biofilms, on abiotic surfaces, e.g., for disinfection and cleaning purposes.

## Claims

### Claim 1

A method for combating biofilm, said method comprising contacting said biofilm with an alginate oligomer.

### Claim 2 (depends on 1)

The method of claim 1, wherein said biofilm is on an animate or inanimate surface.

### Claim 3 (depends on 1, 2)

The method of any one of claim 1 or 2, wherein the biofilm is on a surface selected from surfaces of food or drink processing, preparation, storage or dispensing machinery or equipment, surfaces of air conditioning apparatus, surfaces of industrial machinery, surfaces of storage tanks, surfaces of medical or surgical equipment, surfaces of aquatic/marine equipment or the surfaces of buildings and other structures.

### Claim 4 (depends on 3)

The method of any claim 3 wherein the surface is selected from food processing, storage, dispensing or preparation equipment or surfaces, tanks, conveyors, floors, drains, coolers, freezers, equipment surfaces, walls, valves, belts, pipes, air conditioning conduits, cooling apparatus, food or drink dispensing lines, heat exchangers, boat hulls, dental waterlines, oil drilling conduits, contact lenses, contact lens storage cases, catheters, prosthetic devices or implantable medical devices.

### Claim 5

An alginate oligomer for use in the treatment or prevention of a biofilm infection in a subject.

### Claim 6

Use of an alginate oligomer in the manufacture of a medicament for use in the treatment or prevention of a biofilm infection in a subject.

### Claim 7 (depends on 1, 6)

The method, alginate oligomer or use of any one of claim 1 or 6, wherein the alginate oligomer has an average molecular weight of less than 35,000 Daltons, preferably less than 30,000, 25,000 or 20,000 Daltons.

### Claim 8 (depends on 1, 2, 3, 4, 5, 6, 7)

The method, alginate oligomer or use of any one of claims 1 to 7, wherein the alginate oligomer has a number average degree of polymerisation of 2 to 100, preferably 2 to 75, 2 to 50, 2 to 35, or 2 to 30.

### Claim 9 (depends on 1, 2, 3, 4, 5, 6, 7, 8)

The method, alginate oligomer or use of any one of claims 1 to 8, wherein the alginate oligomer has up to 100 monomer residues, and preferably is a 2- to 35-mer, 2- to 30-mer, 3- to 35-mer, 3- to 28-mer, 4- to 25-mer, 6- to 22-mer, 8- to 20-mer, or 10- to 15-mer.

### Claim 10 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9)

The method, alginate oligomer or use of any one of claims 1 to 9, wherein the alginate oligomer has at least 30% G residues, or at least 70% G residues, preferably 30 to 70% G residues or 70 to 100% G residues.

### Claim 11 (depends on 5, 6, 7, 8, 9, 10)

The alginate oligomer or use of any one of claims 5 to 10, wherein the biofilm is in or on an internal or external body surface.

### Claim 12 (depends on 11)

The, alginate oligomer or use of claim 11, wherein the internal or external body surface is selected from a surface in the oral cavity, the reproductive tract, the urinary tract, the respiratory tract, the gastrointestinal tract, the peritoneum, the middle ear, the prostate, vascular intima, conjunctiva, corneal tissue, lung tissue, heart valves, skin, scalp, nails or the interior of wounds.

### Claim 13 (depends on 5, 6, 7, 8, 9, 10, 11, 12)

The alginate oligomer or use of any one of claims 5 to 12 wherein the subject is a subject selected from a subject with a pre-established infection, an immunocompromised subject, a subject undergoing intensive or critical care, a subject suffering from trauma, a subject with a burn, a subject with an acute and/or chronic wound, a neonatal subject, an elderly subject, a subject with cancer, a subject suffering from an auto-immune condition, a subject with reduced or abrogated epithelial or endothelial secretion and/or secretion clearance or a subject fitted with a medical device.

### Claim 14 (depends on 13)

The alginate oligomer or use of claim 13 wherein the subject is selected from a subject with a condition selected from HIV, sepsis, septic shock, AIDS, a cancer of the immune system, rheumatoid arthritis, diabetes mellitus type I, Crohn's disease, COPD, bronchitis, cystic fibrosis, emphysema, lung cancer, asthma, pneumonia and sinusitis, a subject preparing for, undergoing, or recovering from chemotherapy and/or radiotherapy, an organ transplant subject, a subject resident in a healthcare institution or a smoker.

### Claim 15 (depends on 5, 6, 7, 8, 9, 10, 11, 12, 13)

The alginate oligomer or use as claimed in any one of claims 5 to 13 wherein said alginate oligomer is used to treat and/or prevent biofilm infection in wounds and/or burns or in an in-dwelling medical device

### Claim 16 (depends on 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15)

The alginate oligomer or use of any one of claims 5 to 15 wherein the biofilm infection is a Pseudomonas, e.g. Pseudomonas aeruginosa infection.

### Claim 17 (depends on 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16)

The alginate oligomer or use as claimed in any one of claims 5 to 16 wherein the alginate oligomer is used in the treatment and/or prevention of dental plaque, gingivitis, periodontitis, native valve endocarditis, acute otitis media, chronic bacterial prostatitis, pneumonia, asthma or device-related infection associated with implantable and/or prosthetic medical devices or tissue replacements.

### Claim 18 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17)

The method, alginate oligomer or use of any one of claims 1 to 17, wherein said alginate oligomer is used in combination with an anti-microbial agent.

### Claim 19 (depends on 18)

The method, alginate oligomer or use of claim 18, wherein the anti-microbial agent is an antibiotic or an anti-fungal agent or an antiseptic, disinfectant, sterilising or cleaning agent.

### Claim 20 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19)

The method, alginate oligomer or use of any one of claims 1 to 19, wherein the alginate oligomer is used in combination with at least one other biofilm-disrupting agent and/or mucosal viscosity-reducing agent, preferably selected from proteases, nucleases, lipases, enzymes capable of degrading polysaccharides, gelsolin, thiol reducing agents, an acetylcysteine, sodium chloride, an uncharged low molecular weight polysaccharide, or an anionic polyamino acid, and a nitric oxide precursor or synthesis stimulator.

### Claim 21 (depends on 20)

The method, alginate oligomer or use of claim 20 wherein said alginate oligomer is used in combination with an alginate lyase and/or a DNase enzyme.

### Claim 22 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21)

The method, alginate oligomer, or use of any one of claims 1 to 21, wherein said alginate oligomer is used in combination with a further therapeutically active agent, preferably an immunostimulatory agent, a growth factor or an anti-inflammatory agent.

### Claim 23 (depends on 1, 5, 7, 8, 9, 10)

A product containing an alginate oligomer as defined in any one of claims 1, 5 or 7 to 10 and a second active agent as a combined preparation for separate, simultaneous or sequential use in combating biofilm or treating or preventing biofilm infection in a subject.

### Claim 24 (depends on 18, 19, 20, 21, 22, 23)

The product of claim 23, wherein the active agent is as defined in any one of claims 18 to 22.

### Claim 25 (depends on 23, 24)

The product of any one of claim 23 or 24 in the form of a hypertonic saline solution, an inhalable solution, an inhalable powder, a nasal spray, a debridement composition, a topical composition, a toothpaste or a mouthwash.

### Claim 26 (depends on 1, 2, 3, 4, 5, 7, 8, 9, 10)

A product comprising an inanimate surface as defined in any one of claims 2 to 4 that comprises or has been pretreated with an alginate oligomer as defined in any one of claims 1, 5 or 7 to 10.

### Claim 27 (depends on 1, 5, 7, 8, 9, 10)

A debridement composition containing an alginate oligomer as defined in any one of claims 1, 5 or 7 to 10.
